Categories

CEO Mark Capone talks about the primary challenges facing the molecular diagnostics industry and Myriad’s role as an industry leader in addressing these challenges.

Continue Reading

CEO Mark Capone describes Myriad’s efforts to ensure that patients have access to our tests because we understand how the tests can transform their lives. “That’s why we’ve put in place some of the leading financial assistance programs in the industry.”

Continue Reading

CEO Mark Capone explains what personalized medicine is and the role of genetics in tailoring and improving treatments for individual patients. “Historically, we would take a one-size-fits-all approach for all patients, but now, with personalized medicine, we can fundamentally change that approach.”

Continue Reading

Myriad CEO Mark Capone notes that the current healthcare system in the U.S. is one of the most effective in the world, but also one of the most inefficient. Molecular diagnostics can help deliver greater efficiency, as well as provide important information for consumers to use in making decisions about their own healthcare.

Continue Reading

CEO Mark Capone talks about the importance we place on research collaborations and the role molecular diagnostics play in tailoring treatments for patients. “Research collaborations are part of the reason that we’ve been so successful in some of the pioneering discoveries that we have made at Myriad.”

Continue Reading

CEO Mark Capone describes Myriad’s innovative role in the development of molecular diagnostics. “We actually invented the research- based, education-centric business model for the diagnostic industry.”

Continue Reading


CEO Mark Capone tells the story of one patient and how genetic testing might have saved her life, as well as how it impacted the life of her daughter. “The story reminds me how important our efforts are here at Myriad.”

Continue Reading

CEO Mark Capone describes the unique Myriad culture and what the “DNA of a Myriadian” means to us. “We recognize that every single thing we do every day, there’s a patient at the other end of our work and that what we do matters to that patient.”

Continue Reading

CEO Mark Capone looks at the pioneering role Myriad is playing a as we enter the golden era of molecular diagnostics and what he envisions for our future. “In the next five years, there will be incredible discoveries and we are going to transform the lives of our patients around the world in ways that…

Continue Reading